title: Zolmitriptan (Zomig).
abstract: New triptans are being released in rapid succession with each addition demonstrating some specific pharmacokinetic properties, which may be translated into clinical advantages. Zolmitriptan (Zomig) offers a range of alternatives to migraine sufferers. The conventional tablet is consistently effective across a wide range of migraine subtypes. The orally disintegrating tablet offers an effective option for those migraineurs who are nauseated or need to take their medication earlier in the course of their migraine. Since it can be taken without fluid, the orally disintegrating tablet may be consistently used early in the migraine attack when the pain is still mild. The nasal spray aggregates all the benefits of the oral formulations and has a faster onset of action. The 5-mg dose of all three forms of zolmitriptan offers additional benefits over the 2.5-mg dose at early time points. The physician can now choose the optimum route of delivery of zolmitriptan to stop the headache, increase the likelihood of reducing disability and restore the patient to complete functionality.
authors.affiliation: College of Physicians and Surgeons, Columbia University, New York, NY, USA. alanrapoport@nech.net
authors.forename: Alan M
authors.initials: AM
authors.lastname: Rapoport
authors.forename: Marcelo E
authors.initials: ME
authors.lastname: Bigal
authors.forename: Stewart J
authors.initials: SJ
authors.lastname: Tepper
authors.forename: Fred D
authors.initials: FD
authors.lastname: Sheftell
mesh_terms: D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006261:Headache / Q000188:drug therapy* / Q000191:economics / Q000378:metabolism; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000191:economics / Q000378:metabolism; D023303:Oxazolidinones / Q000008:administration & dosage* / Q000009:adverse effects* / Q000191:economics / Q000493:pharmacokinetics; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage* / Q000009:adverse effects* / Q000191:economics / Q000493:pharmacokinetics; D016896:Treatment Outcome; D014363:Tryptamines / Q000008:administration & dosage* / Q000009:adverse effects* / Q000191:economics / Q000493:pharmacokinetics
chemical_list: D023303:Oxazolidinones; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C089750:zolmitriptan